EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema

Thursday, November 7, 2013 1 min read

Key Takeaway: EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema

Full Press Release Details

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Diabetic Macular Edema.